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ABSTRACT 16 
Recently, the availability of protocols supporting genetic complementation of Eimeria has raised the 17 
prospect of generating transgenic parasite lines which can function as vaccine vectors, expressing and 18 
delivering heterologous proteins. Complementation with sequences encoding immunoprotective 19 
antigens from other Eimeria spp. offers an opportunity to reduce the complexity of species/strains in 20 
anticoccidial vaccines. Herein, we characterise and evaluate EtAMA1 and EtAMA2, two members of 21 
the apical membrane antigen (AMA) family of parasite surface proteins from Eimeria tenella. Both 22 
proteins are stage-regulated, and the sporozoite-specific EtAMA1 is effective at inducing partial 23 
protection against homologous challenge with E. tenella when used as a recombinant protein vaccine, 24 
whereas the merozoite-specific EtAMA2 is not. In order to test the ability of transgenic parasites to 25 
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confer heterologous protection, E. tenella parasites were complemented with EmAMA1, the 26 
sporozoite-specific orthologue of EtAMA1 from E. maxima, coupled with different delivery signals to 27 
modify its trafficking and improve antigen exposure to the host immune system. Vaccination of 28 
chickens using these transgenic parasites conferred partial protection against E. maxima challenge, 29 
with levels of efficacy comparable to those obtained using recombinant protein or DNA vaccines. In 30 
the present work we provide evidence for the first known time of the ability of transgenic Eimeria to 31 
induce cross protection against different Eimeria spp. Genetically complemented Eimeria provide a 32 
powerful tool to streamline the complex multi-valent anticoccidial vaccine formulations that are 33 
currently available in the market by generating parasite lines expressing vaccine targets from multiple 34 
eimerian species.  35 
 36 
HIGHLIGHTS  37 
 Eimeria tenella harbours four different stage-specific AMA1 paralogues. 38 
 EtAMA1, but not EtAMA2, is involved in sporozoite invasion. 39 
 EtAMA1, but not EtAMA2, induces significant protection against E. tenella challenge. 40 
 Vaccination with transgenic E. tenella [EmAMA1] parasites induces partial protection against 41 
challenge with Eimeria maxima. 42 
Keywords: Eimeria tenella, Eimeria maxima, Apical membrane antigen, AMA1, AMA2, Vaccine 43 
delivery vector, Cross protection, Heterologous protection 44 
 45 
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 49 
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1. Introduction 52 
Coccidiosis is caused by apicomplexan parasites of the genus Eimeria.  Seven species replicate 53 
in chickens resulting in acute, self-limiting, enteritis that ranges in symptoms and severity depending 54 
on the species and infective dose of parasite, and the age, gender and genotype of the host.  55 
Recovered animals develop immunity that protects them against challenge with the same species of 56 
parasite, although their productivity may have been severely compromised by the disease, and 57 
repeated rounds of natural re-infection may be needed to induce full immunity (Shirley et al., 2005).  58 
The economic impact of poultry coccidiosis is estimated at >£2 billion per annum due to productivity 59 
losses combined with the costs of prevention and/or therapy (Williams et al., 1999; Dalloul and 60 
Lillehoj, 2006).  In-feed chemoprophylaxis remains the main method of control, but concerns about 61 
drug residues in the food chain, widespread drug resistance, and legislative restrictions on the 62 
prophylactic use of ionophore antibiotics in poultry, all have major impacts (Chapman, 1997; Jenkins 63 
et al., 2017b).  Oral vaccination with formulations of live wild-type or attenuated parasites is highly 64 
effective, but lack of cross-protective immunity means vaccines need to include vaccine lines of all 65 
Eimeria spp. that pose a risk during the lifetime of the chicken. As each vaccine line requires 66 
independent passage through pathogen-free chickens, vaccines are relatively costly to make. The 67 
uptake of commercial vaccines within the global broiler sector remains low, and there is an urgent 68 
need to develop cheaper, scalable vaccines (Blake and Tomley, 2014).  69 
Previously we have shown that transgenic populations of Eimeria parasites can express and 70 
deliver vaccine antigens from Campylobacter jejuni, infectious bursal disease virus (IBDV) and 71 
infectious laryngotracheitis virus (ILTV) to chickens (Clark et al., 2012; Marugan-Hernandez et al., 72 
2016). This technology has the potential to streamline current chicken coccidiosis vaccines, by 73 
reducing the complexity of existing formulations (with up to eight different parasites) to a single or 74 
small number of parasite lines that express immunoprotective antigens from all the relevant species 75 
of Eimeria. We are now able to demonstrate the first important step in the development of such a 76 
multivalent live vaccine by showing that expression in Eimeria tenella of a single antigen (EmAMA1) 77 
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from Eimeria maxima is sufficient to induce statistically significant partial protection against challenge 78 
with E. maxima oocysts that is broadly equivalent to that obtained using the same antigen in other 79 
vaccine platforms.  80 
To date no cross-protective parasite antigens have been described, but several induce 81 
between 30 and 70% immune protection against homologous Eimeria challenge when tested 82 
experimentally with diverse delivery platforms (Blake and Tomley, 2014). The most promising antigens 83 
are derived from early endogenous stages of the Eimeria lifecycle (sporozoite and first generation 84 
schizont), which correlates with the findings observed in naturally infected chickens, where these 85 
stages induce the strongest anti-Eimeria immunity (McDonald et al., 1986, 1988). Several of these 86 
antigens have critical roles in host-parasite interactions including proteins that traffic to the parasite 87 
surface and beyond via the secretory microneme (MIC) organelles such as MIC2 (Sathish et al., 2011), 88 
MIC3 (Lai et al., 2011), MIC4 (Witcombe et al., 2004), and apical membrane antigen (AMA)1, which 89 
achieves around 45% immunoprotective capacity against homologous challenge with E. maxima 90 
(Blake et al., 2011; Li et al., 2013) or Eimeria brunetti (Hoan et al., 2014).  91 
AMAs are a family of proteins expressed by phylogenetically distinct classes of obligate 92 
intracellular apicomplexans including species of Plasmodium and the zoonotic coccidian Toxoplasma 93 
gondii, where they are regarded as strong vaccine candidates (Remarque et al., 2008; Zhang et al., 94 
2015). These proteins are critical for the formation and maintenance of the moving junction, a stable 95 
focus of adhesion between parasite and host cell membranes through which the parasite glides into 96 
its intracellular vacuole (Aikawa et al., 1978; Besteiro et al., 2009; Tyler and Boothroyd, 2011). 97 
Plasmodium falciparum AMA1 exhibits very high levels of genetic polymorphism which poses a major 98 
challenge for vaccine development, hence recent trials have included co-administration of several 99 
PfAMA1 allelic variants (Faber et al, 2016). In contrast, a recent study of genetic variation in E. tenella 100 
identified little intrinsic polymorphism at the ama1 locus ETH_00007745 (ToxoDB, (Blake et al., 2015)) 101 
and we now report similar findings for the locus in E. maxima (GenBank accession number FN813221). 102 
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Proteomic analysis of E. tenella initially identified two dominant stage-regulated AMAs 103 
specific for either sporozoites (EtAMA1, ToxoDB Accesion number ETH_00007745) or merozoites 104 
(EtAMA2, ToxoDB Accesion number ETH_000048600) (Lal et al., 2009; Oakes et al., 2013). More 105 
recently, genomic and phylogenetic analysis defined four classes of AMA paralogues (AMA1-4) that 106 
are conserved across haemosporine and coccidian apicomplexans, including Eimeria (Parker et al., 107 
2016). Polyclonal antiserum against recombinant EtAMA1 were shown to have inhibitory effects on 108 
sporozoite invasion of cultured cells (Jiang et al., 2012), however the serum reacted on western blots 109 
and IFAT with both sporozoite and merozoite antigens, suggesting either that EtAMA1 protein is 110 
expressed by both parasite stages or that the serum recognises more than one AMA paralogue. In this 111 
paper we have clarified the stage-specific nature of these two dominant AMAs expressed by E. tenella 112 
and show that whilst sporozoite-specific EtAMA1 induces partial immunoprotection against 113 
homologous parasite challenge, merozoite-specific EtAMA2 does not. 114 
The focus of the present work was thus two-fold. First, to characterise and test the potential 115 
of the two most abundantly expressed AMA paralogues of E. tenella (EtAMA1 and EtAMA2) as 116 
recombinant vaccines against homologous challenge (E. tenella) in chickens. Subsequently, armed 117 
with the information that vaccination with EtAMA1, but not EtAMA2, significantly reduces the ability 118 
of E. tenella challenge parasites to replicate, we generated transgenic populations of E. tenella that 119 
express the orthologous sporozoite-specific AMA1 protein from E. maxima and tested these as live 120 
vectored vaccines, showing that they confer a similar level of partial protection against heterologous 121 
challenge (E. maxima). These results confirm the vaccine potential of AMA antigens for coccidiosis and 122 
offer new opportunities for the development of multivalent vaccines against all the Eimeria spp. with 123 
relevance to the poultry industry. 124 
 125 
 126 
 127 
 128 
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2. Materials and methods 129 
2.1. Parasites and birds 130 
Oocysts of the Houghton (H) and Wisconsin (Wis) strains of E. tenella, and the Weybridge (W) 131 
strain of E. maxima were propagated by regular in vivo passage through three weeks old Light Sussex 132 
or Lohmann Selected Leghorn (LSL) chickens reared under specific pathogen-free conditions (Long et 133 
al., 1976). Oocysts were recovered and sporulated, and sporozoites were purified through columns of 134 
nylon wool and DE-52, using standard methods (Shirley et al., 1995). Second generation merozoites 135 
from E. tenella parasites were recovered from the intestines of chickens 112 h p.i. by trypsinisation 136 
(Shirley et al., 1995). Apical organelles (micronemes and rhoptries) were isolated from sporozoites 137 
and purified by sucrose-density ultracentrifugation as previously described (Kawazoe et al., 1992).  138 
 139 
2.2. Sequence analysis  140 
EtAMA1 (ToxoDB Accesion number ETH_00007745) and EtAMA2 (ToxoDB Accesion number 141 
ETH_00004860) protein sequences were aligned using the Multiple Sequence Comparison in the Log-142 
Expectation tool (MUSCLE, www.ebi.ac.uk) and edited using the BioEdit software v7·1.1. This program 143 
was also used to estimate the identity and similarity percentages through the BLOSUM62 matrix. 144 
 145 
2.3. Isolation of nucleic acids and proteins, and synthesis of complementary DNA from oocysts 146 
Genomic DNA (gDNA) and total RNA were extracted from oocysts using the TRIzol® reagent 147 
(Invitrogen, Paisley, UK) as detailed previously (Marugan-Hernandez et al., 2016). Protein extracts 148 
from sporozoites and merozoites were obtained following standard procedures (Tomley, 1994).  149 
Complementary DNA (cDNA) was also generated using the SuperScript II® reverse transcriptase and 150 
random hexamer primers (Invitrogen) as previously described (Marugan-Hernandez et al., 2016). 151 
 152 
2.4. Recombinant expression of EtAMA1 and EtAMA2 153 
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The extracellular domains of EtAMA1 (ser16-gly446, ETH_00007745 in ToxoDB) and EtAMA2 154 
(cys15-gly452, ETH_00004860) were amplified from sporozoite or merozoite cDNA by PCR using the 155 
Platinum Taq DNA Polymerase High Fidelity® (Invitrogen) and the following primers (5’-3’): 156 
ATAGGATCCGAGCTGCGCAGGGCCGGCAGCA and GCGAAGCTTTTAACCGCCCCCTTTAGACTCGC for 157 
EtAMA1, and ATAGGATCCGTGCATCAGTGCCGTGGCGGCA and 158 
CGCAAGCTTTTAGCCGAAGCTAACGCCCAGGG for EtAMA2 (Sigma-Aldrich, Suffolk, UK).  Primers 159 
incorporated a BamHI site at the 5’ end (underlined), and a TAA stop codon and HindIII site at the 3’ 160 
end. The digested, gel purified (Qiagen, West Sussex, UK) PCR products were ligated to a pET32b (+) 161 
vector that had been previously linearised by double digestion with BamHI and HindIII (New England 162 
BioLabs, Hertfordshire, UK). EtAMA1 and EtAMA2 sequences were ligated to pET32b (+) by T4 ligase 163 
(Promega, Hampshire, UK), propagated in Escherichia coli XL1-Blue competent cells (Stratagene, 164 
California, USA), purified using the QIAprep Spin Miniprep kit (Qiagen), and checked by restriction 165 
analyses using BamHI and HindIII.  Recombinant EtAMA1 and EtAMA2 were produced in transformed 166 
BL21(DE3)pLysS cells (Novagen, Hertfordshire, UK) and purified using HisTrap FF purification columns 167 
(GE Healthcare, Buckinghamshire, UK) following standard procedures (Blake et al., 2011).  Proteins 168 
were dialysed extensively against PBS before use.   169 
 170 
2.5. Generation of polyclonal antibodies against EtAMA1 and EtAMA2 171 
Hyperimmune antisera were raised in mice (EtAMA1 and EtAMA2), chickens (EtAMA1 only), 172 
or rabbits (EmAMA1) against HisTrap FF purified recombinant proteins (see Section 2.4and (Blake et 173 
al., 2011)). Groups of three or four animals were immunised three times at fortnightly intervals with 174 
between 10 and 50 µg of soluble antigen suspended in 100 µl of PBS and mixed with an equal volume 175 
of Titremax gold (first immunisation) or Freund’s incomplete adjuvant (second and third 176 
immunisations) (Kawazoe et al., 1992). Animals were bled 7 days after the second and third 177 
immunisations and all sera screened by western blotting against solubilised whole sporozoite and 178 
merozoite proteins. 179 
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2.6. Indirect immunofluorescence (IFAT) 180 
Purified E. tenella sporozoites were fixed in 3% paraformaldehyde in PBS for 10 min then 20 181 
µL spots of the suspension were dried onto glass coverslips. Dried parasites were permeabilised by 182 
immersion in ice-cold methanol for 5 min, followed by rehydration in PBS for 20 min. IFAT was carried 183 
out as described (Bumstead and Tomley, 2000) using antiserum to EtAMA1 or EtAMA2.  The DNA stain 184 
DAPI (4', 6’-diamidino-2 phenylindole) was included in the second antibody incubation step. Coverslips 185 
were air dried, mounted on Vectashield (Vector Laboratories, Peterborough, UK) and photographed 186 
at ×1,000 magnification under UV light using a Leitz fluorescence microscope. Alternatively, tissue 187 
sections of infected caeca containing second generation schizonts as used for merozoite harvest were 188 
de-waxed and pressure cooked. All samples were treated with PBS-1% BSA to block non-specific 189 
staining, exposed to primary antibody for 1 h and then, after washing, were incubated with FITC-190 
conjugated anti-chicken or anti-mouse-IgG (Sigma-Aldrich). Some samples were counterstained with 191 
DAPI prior to examination. Coverslips and sections were examined with a Zeiss Axioskop microscope, 192 
and pictures were taken with a cooled CCD camera using Improvision Openlab software.  193 
 194 
2.7. In vitro secretion assays 195 
Freshly excysted E. tenella H sporozoites were purified, resuspended at 108/ml in HAMs F9 196 
media (Sigma-Aldrich) with or without 1% FCS supplementation (Sigma-Aldrich), and incubated at 41 197 
ºC. Supernatants were removed at 0, 10 and 30 min post-incubation, clarified by centrifugation at 198 
10,000 g for 10 min at 4 ºC, and then stored at -20 ºC until examined by SDS-PAGE and western blotting 199 
(as described in Section 2.10). Rabbit antiserum against the E. tenella microneme protein 3 (EtMIC3) 200 
was used as a positive control for secretion (Lai et al., 2011) and against the E. tenella heat shock 201 
protein 70 (EtHSP70) protein as a control for inadvertent sporozoite lysis (Dunn et al., 1995; Bumstead 202 
and Tomley, 2000). 203 
 204 
 205 
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2.8. In vitro sporozoite inhibition assays 206 
Wells of 96-well flat-bottomed plates (Nunc, Roskilde, Denmark) were seeded with 100 µl of 207 
a suspension of Madin Darby Bovine Kidney (MDBK) cells (6 x 105/ml) in HAMs F-12 medium (Sigma-208 
Aldrich) and incubated at 41 ºC until the cells were settled and monolayers reached ~85% confluency. 209 
Freshly hatched E. tenella sporozoites were suspended at 106/ml in HAMs F-12 supplemented with 210 
dilutions of anti-EtAMA1 or anti-EtAMA2 mouse sera (1/50 to 1/800). Alternatively, freshly plated 211 
MDBK cell monolayers were exposed to medium supplemented with dilutions of EtAMA1 or EtAMA2 212 
recombinant protein (1 to 0.625 µg/ml). For all treatments, parasites or cells were incubated in 213 
triplicate for 15 min at room temperature. A mouse antibody against parasite enolyl reductase (ENR) 214 
and the recombinant thioredoxin protein were included as control treatments for each respective 215 
protocol. The incubation medium was removed from each well, replaced with 200 µl of the 216 
appropriate pre-incubated sporozoite suspension and the infected monolayers returned to 41 ºC. 217 
Infected cultures were incubated for 48 h and the overall inhibition of parasite growth measured by 218 
comparison of the incorporation of labelled uracil into untreated cultures, using well established 219 
procedures (Schmatz et al., 1986). In this case infected monolayers were spiked with 1 μCi per well of 220 
[3H] uracil at 24 h p.i., then returned to 41 ºC for a further 24 h at which time cells were lysed and 221 
tritium incorporation was counted. Data were analysed using the Tukey's multiple comparisons test 222 
from the GraphPad Prism software (version 7.02). 223 
 224 
2.9. In vivo EtAMA1 and EtAMA2 immunisation trials  225 
Coccidia-free Light Sussex chickens were housed within specific pathogen-free (SPF), coccidia-226 
free conditions in groups of four (experiment one) or five (experiment two). Chickens were immunised 227 
at one, three and 5 weeks of age by s.c. injection with 100 µg of the corresponding vaccine antigen 228 
(Table 1). The first two preparations were made up to a volume of 0.5 ml and emulsified with 0.5 ml 229 
of TiterMax adjuvant (Sigma-Aldrich) except for Group 4, where 0.25 ml of each antigen was 230 
emulsified separately with 0.25 ml of TiterMax adjuvant and administered together. The last 231 
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preparations were emulsified with Freund’s incomplete adjuvant (Sigma-Aldrich). At 7 weeks of age, 232 
birds were moved into single cages and each chicken was given an oral dose of 250 sporulated E. 233 
tenella H strain oocysts to quantify the effect of the vaccine on parasite replication. Daily faecal 234 
samples were collected from each bird from 5 to 12 days after challenge and the number of oocysts 235 
excreted in the faeces calculated by counting of samples following a standard protocol (Long et al., 236 
1976). Data were analysed by one-way ANOVA with a Tukey’s post-hoc test using the GraphPad Prism 237 
software (version 7.02). 238 
 239 
2.10. SDS- PAGE and western blot  240 
Proteins were electrophoresed through NuPAGE 4–12 % Bis-Tris gels (Invitrogen) in Laemmli 241 
loading buffer (Sigma) using the XCell SureLock Mini-Cell Electrophoresis System (Invitrogen), and then 242 
either stained using Coomasie brilliant blue R-250 (Bio-Rad, Hertfordshire, UK) or transferred to 243 
nitrocellulose membranes (GE Healthcare) in a semi-wet system using the XCell II Blot Module 244 
(Invitrogen). Non-specific binding sites were blocked by overnight incubation in 3% BSA (Sigma-245 
Aldrich) in Tris-buffered saline (TBS)-Tween 0.1%, and then filters were probed with either mouse or 246 
chicken antibodies, diluted in blocking solution, followed by horseradish peroxidase (HRP) conjugated 247 
anti-mouse/chicken second antibodies (Merck Millipore, Hertfordshire, UK). Bound antibody was 248 
visualised by enhanced chemiluminescence (ECL) using Luminata Forte Western HRP substrate (Merck 249 
Millipore) and a G:BOX coupled with GeneSnap 7.12 software (Syngene, Cambridge, UK). 250 
 251 
2.11. Eimeria maxima AMA1 amplification and cloning 252 
The coding sequence of the E. maxima AMA1 ectodomain (EmAMA1, his32-phe446, GenBank 253 
Accesion number FN813221.1) was amplified from the pET32b-EmAMA1 plasmid (Blake et al., 2011) 254 
and flanked with XbaI restriction sites (underlined) by PCR using the primers (5’-3’): 255 
GCTCTAGACACCAGGGTCACACAGAA and GCTCTAGAAAAGCCGCCTTCACACCG (Sigma-Aldrich). A 1,269 256 
bp fragment was amplified using the Platinum Taq DNA Polymerase High Fidelity® (Invitrogen). The 257 
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PCR product was resolved by agarose gel electrophoresis, manually excised under UV light and purified 258 
using the MinElute Gel Extraction kit (Qiagen). Then, it was cloned using the pGEM®-T Easy vector 259 
system (Promega), propagated in E. coli XL1-Blue competent cells (Stratagene), purified using the 260 
QIAprep Spin Miniprep kit (Qiagen), and sequenced (GATC Biotech, London, UK) as described by the 261 
manufacturers.  Sequence analysis was done using CLC Main Workbench (Qiagen).  262 
 263 
2.12. Plasmid constructs for transgene expression of EmAMA1 in E. tenella 264 
Three different core plasmids were used for E. tenella transfection as previously described 265 
(Marugan-Hernandez et al., 2017). In brief, all the plasmids carried the mCitrine reporter downstream 266 
of the E. tenella microneme protein (EtMIC) 1 5’ promoter region, and the mCherry reporter 267 
downstream of the 5’EtMIC2 promoter region, preceded by the XbaI restriction site, and flanked with 268 
varying combinations of two delivery signals: the signal peptide of the EtMIC2 protein (SP2), and the 269 
glycosylphosphatidylinositol anchor of the EtSAG1 protein (GPI) (Fig. 1A-C).  270 
The coding sequence of the EmAMA1 ectodomain was cloned into the XbaI site of the three 271 
core constructs and therefore fused to the mCherry reporter (Fig. 1). For this purpose, the pGEM-T-272 
EmAMA1 plasmid was digested with XbaI (New England BioLabs) following the manufacturer’s 273 
protocol, and the XbaI-EmAMA1-XbaI insert was purified from agarose gels as described above. The 274 
three core constructs were also digested with XbaI (single restriction site), treated with calf intestinal 275 
alkaline phosphatase (New England BioLabs) according to the manufacturer’s instructions, and 276 
purified from agarose gels. The ligation of the EmAMA1 sequence into the core plasmids was carried 277 
out using the T4 ligase (Promega) as detailed by the manufacturer. The three new constructs were 278 
also propagated in XL1-Blue competent cells, mini-prepped, characterized by restriction analyses to 279 
determine the insertion directionality using the NdeI enzyme (New England BioLabs), and sequenced 280 
to check that the insert reading frame had not been altered by cloning. Final plasmids were prepared 281 
for transfection using a Midi Prep Kit (Qiagen), digested for linearization with ScaI (New England 282 
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BioLabs), precipitated in ethanol-sodium acetate (Marugan-Hernandez et al., 2017) and quantified by 283 
NanoDrop (Thermo Scientific). 284 
 285 
2.13. Drug selection of mutant parasites 286 
A plasmid carrying the mutant Toxoplama gondii dihydrofolate reductase–thymidylate 287 
synthase (DHFR-TSm2m3) gene that confers resistance to pyrimethamine (Fig. 1D) (Clark et al., 2008) 288 
was also prepared for co-transfection using a Midi Prep Kit, digested for linearization with PsiI (New 289 
England BioLabs), precipitated in ethanol-sodium acetate and quantified by NanoDrop. 290 
 291 
2.14. Preparation of E. tenella Wis sporozoites expressing EmAMA1 protein 292 
Transfection of freshly hatched E. tenella Wis strain sporozoites was carried out by restriction 293 
enzyme-mediated integration (REMI) using 16-well strips and the programme EO114 of the 294 
Nucleofector 4D (Lonza, Basel, Switzerland) as described previously (Marugan-Hernandez et al., 2016). 295 
Briefly, 1×106 sporozoites were electroporated in duplicate with 10 µg of ScaI and PsiI-digested 296 
plasmids (carrying the EmAMA1 sequence with different delivery signals, and the DHFR-TSm2m3 297 
resistance gene, respectively) together with 6 U of the ScaI and PsiI restriction enzymes in Lonza buffer 298 
P3. Shocked parasites were left for 20 min at room temperature in RPMI medium (Sigma-Aldrich), and 299 
then sporozoite survival was estimated by microscopy using 0.02% Trypan blue dye (Invitrogen) 300 
(Marugan-Hernandez et al., 2017). In order to obtain stable transgenic populations, duplicated wells 301 
were pooled together post-transfection and used to infect two birds by the cloaca (0.75×106 302 
sporozoites/bird). After 24 h, birds were in-feed supplemented with pyrimethamine for 6 days (150 303 
ppm, Sigma-Aldrich) (Clark et al., 2008). Oocysts were harvested 7 days after infection, sporulated and 304 
used for a subsequent in vivo passage after population enrichment for fluorescent parasites by 305 
fluorescence-activated cell sorting (FACS) (FACS Aria III, BD, Berkshire, UK) (Marugan-Hernandez et al., 306 
2016). 307 
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Transcription of the EmAMA1 W strain coding sequence was determined by reverse 308 
transcription PCR (RT-PCR) using cDNA isolated from the three stable transgenic populations as 309 
described above and employing the primers used for EmAMA1 cloning. To confirm the absence of 310 
gDNA in the cDNA samples, primers for the EtActin gene were designed across an intron such that 311 
gDNA contamination of cDNA would result in amplification of two fragments (358 and 99 bp; 5’ to 3’: 312 
TTGTTGTGGTCTTCCGTCA and GAATCCGGGGAACATAGTAG, Sigma-Aldrich; from (Marugan-Hernandez 313 
et al., 2016)). The EmAMA1 sequence was amplified by PCR using the Platinum Taq DNA Polymerase 314 
(Invitrogen), and the corresponding cDNA at 1/10 dilution. The PCR product was resolved by agarose 315 
gel electrophoresis.  316 
Expression of the EmAMA1 protein fused with mCherry was confirmed by microscopy for the 317 
fluorescent reporter using the fluorescent microscope DMI3000B – DCF365FX (Leica Microsystems, 318 
Milton Keynes, UK). Micrographs of sporulated transgenic oocysts were collected using the SP5 319 
confocal microscope and the Leica Application Suite Advanced Fluorescence software (Leica 320 
Microsystems). Image processing was performed using ImageJ software (NCBI, 321 
http://rsb.info.nih.gov/ij/). 322 
 323 
2.15. In vivo immunisation trial of E. tenella Wis parasites expressing EmAMA1  324 
A total of 42 White Leghorn line 15I chicks (highly susceptible to E. maxima infection, 325 
(Bumstead and Millard, 1992; Smith et al., 2002)); purchased from the National Avian Research 326 
Facility, Edinburgh, UK) were split into six groups of seven in independent wire-floored cages (Table 327 
2). One (Group 1, Et[EmAMA1-Ch]) and two (Group 3, Et[SP2-EmAMA1-Ch-GPI]) chicks were removed 328 
prior to the start of the vaccination trial for husbandry reasons. Birds from groups 1 to 4 were 329 
immunised by oral gavage at days 2, 8, 14 and 21 of age with 100, 500, 3,000, and 5,000 FACS enriched 330 
transgenic EmAMA1 E. tenella sporulated oocysts, respectively, to mimic parasite recycling, whereas 331 
birds from groups 5 to 6 were inoculated with sterile PBS following the same scheme. At day 30, birds 332 
from groups 1 to 5 were challenged with 300 oocysts of the E. maxima W strain to quantify the effect 333 
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of the vaccine on parasite replication. Body weights and serum samples were collected at days 29 (8 334 
days after the final vaccination) and 36 (6 days post-challenge) of age to determine the safety, 335 
immunogenicity, and efficacy of the recombinant vectored vaccines. Also, individual faecal samples 336 
were collected from days 35 to 39 (5 - 8 days post-challenge) to determine the total oocyst output 337 
after E. maxima challenge (Shirley et al., 2005). Data were analysed by one way ANOVA with a Tukey’s 338 
post-hoc test using the GraphPad Prism software (version 7.02). 339 
 340 
2.16. Analysis of immune responses elicited after vaccination with E. tenella Wis parasites expressing 341 
EmAMA1 and after challenge with E. maxima W 342 
 Serum samples collected on day 29 were used to detect IgY responses against EmAMA1 343 
protein by western blot.  All sera (1/50 to 1/400 dilutions) were directed against nitrocellulose 344 
membranes transferred with recombinant EmAMA1 or with E. maxima protein extracts as detailed in 345 
Section 2.10. For E. maxima-based western-blots, rabbit anti-EmAMA1 antiserum was used as the 346 
positive control to detect native EmAMA1 protein in oocyst extracts and compare its recognition 347 
pattern with those obtained using the test serum samples.  348 
In addition, serum samples collected on day 29 and 36 were used to quantify serum IL-10 and 349 
IFN-.  IL-10 ELISA was performed as described previously (Wu et al., 2016). Briefly, assay plates (Nunc 350 
Immuno MaxiSorp) were coated overnight at 4 C with 3 g/ml of capture antibody, incubated with 351 
50 l of two-fold serially diluted standards or serum samples, and incubated with 1 g/ml of 352 
biotinylated detection antibody. The plates were incubated with streptavidin-HRP and developed with 353 
1-Step™ Turbo TMB substrate solution (Thermo Scientific). The reaction was stopped by adding 50 l 354 
of 2N sulphuric acid after 10 min, and assays were read at 450 nm. IFN- levels were measured using 355 
the IFN- chicken matched antibody pair (Thermo Scientific) following the manufacturer’s instruction. 356 
Data were analysed by one-way ANOVA with a Tukey’s post-hoc test using GraphPad Prism software 357 
(version 7.02). Associations between oocyst shedding and cytokine levels were estimated using the 358 
Pearson correlation coefficient with the same software. 359 
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2.17. Genetic characterisation of E. maxima and E. tenella apical membrane antigens 360 
Gene models for the E. tenella apical membrane antigens 2-4 were downloaded from ToxoDB 361 
(Gajria et al., 2008; Parker et al., 2016) and used to identify candidate E. maxima orthologues using 362 
tBLASTx with default parameters in ToxoDB. Coding sequences for EmAMA1 and EtAMA1 were 363 
accessed from GenBank and ToxoDB (FN813221 and ETH_00007745). Transcription profiles were 364 
accessed for all E. tenella genes using published RNAseq data (Reid et al., 2014; Walker et al., 2015). 365 
Signatures of selection were assessed using mean Ka/Ks scores (Eimeria acervulina, E. brunetti, E. 366 
maxima, Eimeria mitis, Eimeria necatrix and Eimeria praecox compared with E. tenella, (Reid et al., 367 
2014)). For E. maxima, additional measures of genetic diversity were calculated using 18 coding 368 
sequences derived from India (n=3), Nigeria (n=2), Spain (n=1) and the UK (n=12) available under the 369 
GenBank accession numbers FN813221-2, LN626985-91 and LT900485-LT900492. Analyses 370 
undertaken using DnaSP v5.10 (Librado and Rozas, 2009) included identification of the number of 371 
variant sites (S) and numbers of non-synonymous (dN) or synonymous (dS) substitutions. Diversity 372 
was defined by calculating the average nucleotide difference (k) and nucleotide diversity (π with the 373 
Jukes Cantor correction).  Allelic diversity was defined by calculating the number of haplotypes (H) and 374 
the associated haplotype diversity (Hd). Neutrality was assessed using Tajima’s D and Fu and Li’s D* 375 
and F* tests with the total number of mutations and significance set at P <0.05. All analyses were 376 
performed as described previously and compared with data published for EtAMA1 (Blake et al., 2015). 377 
 378 
2.18. Ethical statement 379 
This study was carried out in strict accordance with the Animals (Scientific Procedures) Act 380 
1986, an Act of Parliament of the United Kingdom. All animal studies and protocols were approved by 381 
the Royal Veterinary College Animal Welfare & Ethical Review Body (London, UK) and the United 382 
Kingdom Government Home Office under specific project licence. The laboratory work involving 383 
genetic modified organisms (GMO) was conducted under authorization GM9708.1, administered by 384 
the UK Health and Safety Executive.  385 
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3. Results 386 
3.1. Expression of EtAMA genes is stage-regulated 387 
The protein sequences of EtAMA1 and EtAMA2 were compared using the BLOSUM62 matrix, 388 
and displayed low identity and similarity scores (0.338 and 0.474, respectively) (Supplementary Fig. 389 
S1). Samples of unsporulated oocysts (UO, 1.25×105/well), sporulated oocysts (SO, 1.25×105/well), 390 
sporozoites (Sz, 1×106/well) and second generation merozoites (Mz2, 1×106/well) were probed with 391 
hyperimmune mouse serum against rEtAMA1 or rEtAMA2. EtAMA1 was detected in the sporulated 392 
oocyst and sporozoite lanes and was absent from the merozoites. Conversely, EtAMA2 was detected 393 
only in merozoites (Fig. 2A).  Subsequent comparison of RNAseq datasets representing UO, SO, Sz, 394 
Mz2 and gametocyte (Gam) lifecycle stages confirmed these findings, with additional evidence of 395 
stage-specific transcription for EtAMAs 1-4 (Table 3).  Mean Ka/Ks ratios of less than 1.0 were reported 396 
for AMA1 and AMA4, indicating purifying or stabilising selection.  397 
Samples of sporozoites and gradient-enriched preparations of sporozoite micronemes and 398 
rhoptries were probed with hyperimmune mouse and chicken sera raised against the same 399 
preparation of rEtAMA1. The mouse antiserum recognised a single microneme protein of an apparent 400 
molecular mass of ~63 kDa, whereas the chicken antiserum additionally reacted with a protein in the 401 
rhoptry fraction of ~60 kDa (Fig. 2B). EtMIC3 antiserum demonstrated that the rhoptry fraction was 402 
not significantly contaminated with micronemes, and EtHSP70 antiserum (a common contaminant of 403 
rhoptry fractions, (Dunn et al., 1995)) demonstrated that the microneme fraction was not 404 
contaminated with rhoptries. 405 
Immunofluorescent antibody staining of sporozoites with mouse anti-rEtAMA1 showed an 406 
apical localisation within the zoite (Fig. 2C), whereas mouse anti-rEtAMA2 showed clear apical staining 407 
of mature merozoites in caecal sections harvested 114 h p.i. with E. tenella H strain (when second 408 
generation schizogony is underway) (Fig. 2C). Some sections were counterstained with antibodies 409 
against the merozoite surface antigen EtSAG4, to delineate the outline of merozoites within schizonts. 410 
Others were counterstained with antibodies against EtMIC2 to delineate the micronemes. 411 
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Interestingly, EtAMA2 only partially co-localised with EtMIC2, indicating that it may not all be localised 412 
within the microneme organelles or alternatively that the two proteins may be differentially 413 
distributed within the microneme population (Fig. 2C).  A similar phenomenon was previously noted 414 
when co-staining for EtAMA1 and EtMIC3 (Lai et al, 2011). 415 
 416 
3.2. EtAMA1 is secreted by sporozoites and involved in host-cell sporozoite invasion 417 
Freshly excysted and purified sporozoites were incubated with or without FCS for up to 30 418 
min. In the absence of FCS, EtAMA1 was secreted at a low level by sporozoites whereas FCS 419 
supplementation induced rapid secretion into the culture supernatant in a manner typical of E. tenella 420 
microneme proteins (Fig. 2D) (Lai et al., 2011). Pre-treatment of MDBK cells or E. tenella sporozoites 421 
with, respectively, recombinant EtAMA1 (0.5 to 1 µg) or mouse anti rEtAMA1 (1/800 to 1/50 dilution), 422 
resulted in significant reductions in parasite-specific uracil uptake (P < 0.05, Tukey’s post hoc test), 423 
indicative of reduced invasion and/or parasite replication. In contrast, treatment with recombinant 424 
EtAMA2, recombinant thioredoxin, anti rEtAMA2 serum, or anti-ENR serum did not affect uracil 425 
uptake (Fig. 2E). 426 
 427 
3.3. Recombinant EtAMA1 induces an immune response protective against E. tenella challenge 428 
In experiment 1, vaccination with rEtAMA1 induced a significant reduction in oocyst output 429 
after challenge with E. tenella (P < 0.05, one way ANOVA test), reducing oocyst shedding by 77.4% 430 
compared with the non-vaccinated control, whereas no significant differences were found between 431 
chickens vaccinated with rEtAMA2 and non-immunised animals (P > 0.05, one way ANOVA test) (Fig. 432 
3). Similarly, in experiment 2, vaccination with rEtAMA1 or with combined rEtAMA1+rEtAMA2 induced 433 
a significant reduction in oocyst output after challenge with E. tenella (P < 0.05, one wayANOVA test), 434 
reducing oocyst shedding by 76 and 66% compared with the non-vaccinated control, respectively. 435 
Again, no significant differences were found between chickens vaccinated with rEtAMA2 and non-436 
immunised animals (P > 0.05, one way ANOVA test) (Fig. 3). 437 
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3.4. Eimeria tenella can express the foreign antigen EmAMA1 and modify its trafficking when 438 
complemented with appropriate delivery signals 439 
Three populations of transgenic E. tenella parasites expressing EmAMA1 were generated by 440 
transfection and stabilised by sequential passage through chickens medicated with pyrimethamine 441 
(Fig. 4A). The first round of infection resulted in shedding of 20 to 60×106 oocysts/bird 1 week p.i., of 442 
which 1 to 2% expressed the mCitrine reporter.  FACS enrichment of mCitrine expressing parasites 443 
was ~95% efficient and successive in vivo passage of FACS isolated mCitrine-positive parasites under 444 
pyrimethamine selection improved the transgenic proportion of each population from 1 to 2% at 445 
passage 1, to 16 to 42% at passage 3 (Fig. 4A). 446 
Transcription of EmAMA1 mRNA was confirmed by RT-PCR in all three transgenic populations 447 
in the absence of gDNA contamination (Fig. 4C). In addition, expression of the EmAMA1 protein was 448 
indicated by detection of the fused mCherry reporter by fluorescence microscopy (Fig. 4B). In the 449 
three populations, FACS enriched parasites expressed mCitrine as a cytosolic protein, whereas the 450 
expression pattern of mCherry differed among them. Parasites not complemented with delivery 451 
signals expressed the mCherry as a cytosolic protein which co-localised with mCitrine (EmAMA1-Ch in 452 
Fig. 4B). In contrast, populations complemented with the SP2 sequence secreted the mCherry reporter 453 
into the sporocyst cavity (SP2-EmAMA1-Ch and SP2-EmAMA1-Ch-GPI in Fig. 4B). Furthermore, 454 
complementation with the GPI-anchor additionally induced the anchorage of mCherry onto the 455 
sporozoite surface (SP2-EmAMA1-Ch-GPI in Fig. 4B). In all populations both mCitrine and mCherry 456 
were present within cytosolic aggregates, which in some cases were co-localised (Fig. 4B). 457 
 458 
3.5. Vaccination with transgenic E. tenella expressing EmAMA1 protects against challenge by the 459 
antigen donor E. maxima without eliciting specific humoral responses, but reducing serum IL-10 levels 460 
Vaccination with live E. tenella parasites did not result in significant differences in weights 461 
between groups prior to challenge (P > 0.05, one way ANOVA test) indicating no detrimental effect of 462 
the vector. Similarly, no differences in body weight gain were found between groups after challenge 463 
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with E. maxima W strain, as the dose used was deliberately low in order to accurately determine the 464 
vaccination effect on parasite replication ((Blake et al., 2006); P > 0.05, one way ANOVA test) 465 
(Supplementary Fig. S2A and B). Vaccination with all three transgenic E. tenella populations expressing 466 
EmAMA1 resulted in significant reductions in oocyst output after challenge with E. maxima (P < 0.05, 467 
one way ANOVA test), ranging from 45 to 55% compared with the non-vaccinated and the challenged 468 
groups (Fig. 5A).  Pairwise comparisons did not show statistical differences between the three 469 
vaccinated groups (P > 0.05, one way ANOVA test). 470 
Serum samples collected 8 days after final vaccination (day 29) showed variable antibody 471 
reactivity against rEmAMA1 protein within experimental groups, and no reactivity against native 472 
EmAMA1 in E. maxima solubilised protein extracts, suggesting that the observed reduction in parasite 473 
replication after challenge was not mediated by specific humoral responses against EmAMA1 (Fig. 5B). 474 
Similarly, we did not detect enhanced levels of IFN- in serum 8 days after final vaccination (day 29) 475 
or 6 days after challenge (day 36), with equally low concentrations across all groups (under 60 pg/ml, 476 
P > 0.05, one way ANOVA test) (Fig. 5C).  At day 29, all groups displayed low levels of serum IL-10 (P > 477 
0.05, one way ANOVA test) (Fig. 5C) and at 6 days post-challenge (day 36) the average IL-10 serum 478 
levels were lower in all groups immunised with transgenic parasites compared with non-vaccinated 479 
and challenged birds (Fig. 5C). However this reduction was only significant in groups vaccinated with 480 
Et[SP2-EmAMA1-Ch] and Et[SP2-Ch-GPI] parasites (P < 0.05, one way ANOVA test), suggesting that the 481 
effect is not mediated by expression of EmAMA1. A positive correlation was detected between serum 482 
IL-10 levels and oocyst output (64%, P < 0.001, Pearson correlation test, data not shown). 483 
 484 
3.6. Sequence diversity for the anticoccidial vaccine candidate EmAMA1 is limited and comparable to 485 
the E. tenella orthologue 486 
Comparison of 56 E. tenella AMA1 coding sequences previously revealed limited antigenic 487 
diversity and a largely neutral signature of selection (Blake et al., 2015). Here, comparison of 18 488 
EmAMA1 coding sequences from parasites sampled in four countries, across three continents, 489 
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revealed a comparably low level of diversity (Table 4). Specifically, nine EmAMA1 cDNA haplotypes 490 
were identified but total nucleotide diversity was low and no significant signatures of selection were 491 
detected. Analysis of the 1,617 bp coding sequence alignment revealed 10 nucleotide substitutions, 492 
of which three were non-synonymous.  Substitutions of histidine to leucine (amino acid position 81), 493 
isoleucine to methionine (position 133) and glutamic acid to aspartic acid (position 393) were 494 
detected, of which the latter was located close to the glutamic acid to valine (position 386) 495 
substitution described previously in the EtAMA1 amino acid sequence (Blake et al., 2015).  496 
 497 
4. Discussion 498 
In the present work we have characterised the two most highly expressed AMAs of E. tenella, 499 
EtAMA1 (ToxoDB Accession number ETH00007745) and EtAMA2 (ToxoDB Accession number 500 
ETH00004860) and demonstrate, to our knowledge for the first time, that vaccination with sporozoite-501 
specific EtAMA1, but not merozoite-specific EtAMA2, elicits highly significant protection against 502 
homologous challenge with E. tenella.  With this knowledge we went on to establish a proof of concept 503 
for the use of Eimeria parasites as vaccine delivery vectors for heterologous coccidial antigens, 504 
showing that E. tenella parasites expressing EmAMA1 antigen from E. maxima are able to induce 505 
partial protection in all the vaccinated birds against heterologous challenge infection with E. maxima. 506 
A polyclonal mouse serum raised against rEtAMA1 detected native EtAMA1 in sporulated 507 
oocysts and sporozoites, but not in merozoites, and conversely mouse serum against rEtAMA2, 508 
detected native EtAMA2 solely in merozoites. These results agree with previous proteomic and 509 
transcriptomic data and confirm that these two EtAMA paralogues are tightly stage-regulated (Lal et 510 
al., 2009; Reid et al., 2014). Interestingly a second antibody raised against rEtAMA1 in chickens 511 
detected an additional sporozoite protein (Fig. 2B) indicating the potential for cross-reactivity of anti-512 
AMA1 antibodies. This additional protein was not identified, but it could potentially be EtAMA3 or 513 
EtAMA4, both of which are expressed in the sporozoite stage (Table 3). Importantly, we showed that 514 
the mono-specific mouse anti-rEtAMA1 serum as well as rEtAMA1 protein were both efficient at 515 
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reducing sporozoite invasion of cultured cells, in agreement with previous work (Jiang et al., 2012), 516 
whereas anti-rEtAMA2 and -rEtAMA2 protein had no effect on parasite invasion, again indicating the 517 
highly stage-specific nature of the two paralogues. The possession of four AMA paralogs in T. gondii is 518 
proposed to confer exceptional molecular plasticity at the parasite–host-cell interface (Poukchanski 519 
et al., 2013; Lamarque et al., 2014; Parker et al., 2016). In this work, we identified the EtAMA2 gene 520 
in merozoite-derived expressed sequence tags (ESTs) (data not shown) supporting previous 521 
observations based on transcriptomic data (Reid et al., 2014), and confirmed that EtAMA2 protein is 522 
found in merozoites by western blotting and IFAT experiments (Lal et al., 2009). Intriguingly, RNAseq 523 
evidence published by others also indicates EtAMA2 gene transcription in gametocytes, although the 524 
precise function of an AMA paralogue in this stage of the parasite is unclear (Walker et al., 2015). All 525 
these findings indicate that E. tenella parasites harbour stage-specific AMA proteins that could be 526 
relevant during specific phases of the parasite cycle. Interestingly, Jiang and colleagues apparently 527 
detected EtAMA1 protein in merozoites and gametes despite transcriptomic evidence discarding this 528 
possibility (Jiang et al., 2012), which could potentially be artefactual and due to their anti-EtAMA1 529 
serum cross-reacting with alternative EtAMA paralogs.  530 
The results obtained in in vitro sporozoite inhibition assays were in line with what was 531 
subsequently observed when rEtAMA1 and rEtAMA2 were used to immunise chickens. Birds 532 
vaccinated with rEtAMA1, but not rEtAMA2, produced significantly fewer oocysts after challenge with 533 
E. tenella, and vaccination with combined rEtAMA1 and rEtAMA2 did not induce any synergistic effect. 534 
Similar promising results have been seen in previous studies where chickens were vaccinated with 535 
AMA1 proteins from E. maxima (DNA, recombinant protein and Bacille Calmette-Guérin -vectored 536 
immunisations) or E. brunetti (DNA immunisation) and vaccine efficacy was measured in a variety of 537 
ways including improved body weight gains and reduced gut lesions after high dose challenge, or 538 
reduced oocyst shedding after low dose challenge (Blake et al., 2011; Li et al., 2013; Hoan et al., 2014). 539 
Given their proven ability to induce robust immunoprotective responses, and the availability 540 
of established methods for vaccine administration, the use of live recombinant Eimeria vectors as 541 
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streamlined vaccines against coccidia in poultry is highly attractive. In earlier studies we demonstrated 542 
that vaccination with E. tenella Wis strain parasites expressing the CjaA protein from Campylobacter 543 
jejuni induced significant protection (86-91%) against homologous challenge infection, regardless of 544 
the number of immunisations (Clark et al., 2012). Subsequently, we showed that E. tenella Wis 545 
parasites expressing the vvVP2 protein from infectious bursal disease virus (IBDV), or glycoprotein I 546 
from infectious laryngotracheitis virus (ILTV), elicited limited but specific humoral responses when 547 
used as vaccines (Marugan-Hernandez et al., 2016). More recently, we carried out extensive work to 548 
improve the Eimeria vector system by inducing higher expression of the transfected gene and 549 
increasing exposure of the transprotein to the host immune system through the use of specific 550 
promoters and delivery signals, respectively (Marugan-Hernandez et al., 2017). The promising results 551 
obtained with EtAMA1 and EmAMA1 subunit vaccines prompted us to test the fitness of this new 552 
delivery system (E. tenella Wis-based) to express the EmAMA1 protein from E. maxima at high levels 553 
and modify the protein trafficking by inducing its secretion and tethering to the sporozoite surface. As 554 
expected, all three transgenic populations transcribed the EmAMA1-mCherry sequence, expressed 555 
the protein at high levels, and displayed differential secretion patterns (Fig. 4). In previous work we 556 
showed that E. tenella parasites expressing the yellow fluorescent protein (YFPmYFP) can be stabilized 557 
after three generations under double selection (Clark et al., 2008). In the present study, the same 558 
number of in vivo passages was insufficient to obtain fully fluorescent populations, although all 559 
populations displayed distinct increases in the percentage of stable transgenic parasites after three 560 
generations (Fig. 4A). We have observed this to be the case for several other co-transfections (data 561 
not published), and hypothesise that it could be due to the disruption of the integrated plasmids 562 
during sporulation, when meiosis takes place under no drug selection. 563 
Previous studies have shown that the immunological activity of AMA1 in Plasmodium 564 
parasites relies on its correct folding (Hodder et al., 2001). While we did not check whether EmAMA1 565 
was properly folded in transgenic populations, we assumed that the use of an E. tenella-based vector 566 
would support appropriate folding of foreign proteins from other Eimeria spp., and according to our 567 
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data this seems to have been the case. We observed similar results in a previous study carried out 568 
with birds that received single or trickle vaccinations with E. tenella Wis parasites expressing EmAMA1 569 
under the control of the EtAMA1 promoter and displayed a reduction in the oocyst output ranging 570 
from 38.4 to 46.9% after challenge with E. maxima W (Supplementary Fig. S3). Furthermore, similar 571 
cross-strain heterologous protection results were observed when E. maxima H strain sporozoites 572 
transiently transfected with a bacterial artificial chromosome (BAC) construct carrying the EmAMA1 573 
sequence from the E. maxima W strain were used as a vaccine (Blake et al., 2011).  All these data offer 574 
promising prospects for the future development of anti-coccidial vaccines based on Eimeria as a 575 
vector. 576 
Interestingly, all three transgenic populations induced similar levels of heterologous 577 
protection after challenge with E. maxima, suggesting that the EmAMA1 protein is similarly processed 578 
by the host immune system regardless of the delivery signal employed. However, sera collected after 579 
vaccination were consistently not reactive against the native EmAMA1 protein within E. maxima 580 
protein extracts (Fig. 5B). These findings correlate with our previous study, in which vaccination with 581 
transgenic Eimeria parasites induced low antibody titres against the transgene (Marugan-Hernandez 582 
et al., 2016), and indicate that this vector system may not be suitable when specific humoral responses 583 
are needed. The role of the humoral response in conferring resistance to coccidiosis is still debated, 584 
but it is clear that antibody titres do not correlate with levels of protection (Lillehoj and Ruff, 1987; 585 
Wallach et al., 1992; Dalloul et al., 2003; Lee et al., 2009a, b). Our study supports this view, since all 586 
vaccinated groups were able to reduce E. maxima replication after challenge despite the absence of 587 
reliably detectable levels of antibodies specific for EmAMA1. 588 
It is well established that Eimeria parasites induce significant increases in IFN- mRNA levels 589 
in the infected tissues (Rothwell et al., 1995; Min et al., 2003), as well as protein levels in serum (Yun 590 
et al., 2000) and peripheral blood leucocytes (Breed et al., 1997). However, we detected little or no 591 
enhanced serum IFN- levels compared to the controls at either day 29 (after four oral vaccinations 592 
with transgenic E. tenella) or day 36 (6 days after challenge with E. maxima). We did not expect to see 593 
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enhanced levels at day 29, as this was 4 weeks after the primary vaccination, but did expect to see 594 
induction of serum IFN- at day 36, as this is reported to increase in serum at 8 days post challenge 595 
with E. maxima (Yun et al., 2000). However, an earlier report did not detect serum IFN- until 20 days 596 
following primary and serial exposure to E. maxima (Yun et al., 2000), thus the timing may vary 597 
according to host strain and parasite dose. Similarly, the trickle vaccination did not affect IL-10 serum 598 
levels at day 29 compared tocontrols (Fig. 5C), and again this is most likely due to the timing of 599 
sampling. In contrast, all challenged birds showed increased serum IL-10 levels at day 36, including 600 
birds immunised with transgenic parasites. Expressed serum IL-10 was lower in all immunised birds 601 
compared to non-immunised birds, irrespective of exposure to EmAMA1. Increased serum IL-10 at 602 
day 36 in all challenged birds may be explained by exposure to different Eimeria spp. at immunisation 603 
and challenge (transgenic E. tenella and E. maxima), effectively indicating different primary infections.  604 
The lower serum IL-10 levels in birds immunised using Et[SP2-Ch-GPI] suggests a low level of cross-605 
protection, which was reflected in oocyst output (17% to 27% reduction; Fig. 5B and Supplementary 606 
Fig. S3). We also observed that increased serum IL-10 levels may lead to increased oocyst shedding, 607 
which agrees with previous findings (Sand et al., 2016), indicating that serum IL-10 levels could be a 608 
potential predictive marker of susceptibility to infection (Wu et al., 2016). 609 
Previous studies have shown that fecundity of Eimeria parasites is reduced as the infective 610 
dose increases due to a ‘crowding effect’, and infection with 250 oocysts is sufficient to induce the 611 
highest level of oocyst shedding (Johnston et al., 2001; Williams, 2001). For this reason, measurement 612 
of oocyst replication after a low-dose challenge is the most sensitive method available for measuring 613 
vaccine efficacy, and is still regarded as a ‘gold standard’ by vaccine regulators. However, this 614 
approach is not suitable for evaluation of factors such as protection against intestinal damage (lesion 615 
score) and body weight gain as shown by a recent study, where infections with similar doses of E. 616 
maxima only induced mild lesions and very low body weight losses (Jenkins et al., 2017a). Future trials 617 
will be required to evaluate protection against more severe challenge doses.  618 
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The confirmation of limited genetic diversity between AMA1 alleles for E. maxima, with no 619 
evidence of significant signatures of selection, mirrors that described previously for E. tenella (Blake 620 
et al., 2015). Antigenic diversity within parasite populations provides the potential for immune escape, 621 
with the greatest likelihood when small numbers of antigens are used in subunit or recombinant 622 
vaccines to induce focused immune responses. The low levels of naturally occurring diversity 623 
described for EtAMA1 have enhanced its candidacy for use in novel anti-coccidial vaccines. While 624 
AMA1 is known to be highly polymorphic within populations of some apicomplexans such as 625 
Plasmodium falciparum (Takala and Plowe, 2009), the low levels of polymorphism and its ability to 626 
induce immune protection described for two Eimeria spp. suggest that AMA1 is a viable vaccine 627 
candidate for all Eimeria spp. which infect chickens, and possibly all Eimeria spp.  628 
Currently the commercial availability of live vaccine formulations is constrained by inherent 629 
limitations in the capacity of production of live parasites, which is especially true where attenuated 630 
vaccines are produced (Williams, 1998). In the broiler sector, where profit margins are very tight, 631 
control measures are still highly dependent on the use of anti-coccidial prophylaxis due to the higher 632 
costs of these vaccines (Sharman et al., 2010; Blake and Tomley, 2014). Therefore, there is a need to 633 
reduce the cost of the available formulations in the market and make them more attractive for this 634 
sector. Herein we show that EtAMA1 is an effective vaccine candidate, provide evidence for the first 635 
time that genetic complementation of E. tenella parasites is a valuable tool to deliver vaccine 636 
candidates from other coccidian species which infect poultry, and demonstrate that this vaccine 637 
platform is able to induce significant levels of heterologous protection after complementation with 638 
EmAMA1. Furthermore, we provide a powerful tool to develop new generation vaccines against 639 
multiple Eimeria spp. as a means to streamline the available formulations in the market, and thus 640 
reduce their cost. In this sense, successful genetic complementation of highly prolific and less 641 
pathogenic species such as Eimeria acervulina would be highly beneficial (Zou et al., 2009). 642 
 643 
 644 
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Figure legends 846 
 847 
Fig. 1. Simplified representation of the plasmids used for Eimeria tenella transfection. (A-C) Core 848 
constructs employed to transfect E. tenella parasites. Scissors represent the location of the unique 849 
XbaI restriction site, used for transgene insertion. In transfected parasites, the mCitrine protein is 850 
expressed as a cytosolic protein and used to select transgenic parasites by flow cytometry, whereas 851 
mCherry, or transgene-mCherry fusion protein, is expressed as a cytosolic protein (with no delivery 852 
signals), secreted into the sporocyst cavity (SP2), or secreted and anchored onto the sporozoite 853 
surface (SP2+GPI) (Clark et al., 2012; Marugan-Hernandez et al., 2017). (D) A plasmid carrying the 854 
mutant Toxoplama gondii dihydrofolate reductase–thymidylate synthase (DHFR-TSm2m3) gene was 855 
used for in vivo selection of transgenic parasites resistant to pyrimethamine treatment (Clark et al., 856 
2008). 857 
 858 
 859 
 860 
 861 
 862 
 863 
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 864 
Fig. 2. Characterisation of the Eimeria tenella apical membrane antigens (EtAMA) 1 and 2. (A) Protein 865 
extracts obtained from unsporulated oocysts (UO), sporulated oocysts (SO), sporozoites (Sz) and 866 
merozoites (Mz) resolved by SDS-PAGE and stained using Coomasie brilliant blue R-250 (1). Detection 867 
of EtAMA1 (2) and EtAMA2 (3) on the same protein extracts by western blotting using specific 868 
hyperimmune mouse sera. EtAMA1 was restricted to sporulated oocysts and sporozoites, whereas 869 
EtAMA2 was only found in merozoites. (B) Detection of EtAMA1 on micronemes (MIC), rhoptries (ROP) 870 
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and sporozoites (Sz) by western blotting. Mouse antiserum recognised a single microneme protein 871 
(~63 kDa). Antibodies raised against the E. tenella microneme protein 3 (EtMIC3) and the E. tenella 872 
heat shock protein 70 (EtHSP70) confirmed that microneme fractions were not contaminated with 873 
rhoptries, and vice versa. (C) Detection of EtAMA1 on sporozoites and EtAMA2 on mature second 874 
generation merozoites by IFAT. Some EtAMA2 sections were counterstained with an antibody against 875 
the E. tenella surface antigen 4 (EtSAG4) to delineate the sporozoites, and some others with an 876 
antibody against the E. tenella microneme protein 2 (EtMIC2) to delineate the micronemes. EtAMA1 877 
and EtAMA2 showed apical localisations within the zoites. EtAMA2 partially co-localised with EtMIC2 878 
in merozoites. Bars represents 10 µm. (D) Detection of EtAMA1 on sporozoites (Sz) and sporozoite 879 
secreted fractions (0-30) by western blotting with or without treatment with FCS (-/+ FCS) and 880 
collected at 0, 10 or 30 min post-incubation. A low level of EtAMA1 secretion was constitutive, but 881 
secretion was strongly induced after FCS supplementation. EtMIC3 detection was used as positive 882 
control of secretion, while EtHSP70 detection was used to show the absence of sporozoite lysis. (E) In 883 
vitro sporozoite inhibition assays using recombinant (r) EtAMA1 and EtAMA2 (1) or specific anti-sera 884 
(2). All the experiments were done in triplicate. The recombinant thioredoxin protein (rThioredoxin) 885 
and a mouse antibody against parasite enolyl reductase (ENR) were included as control treatments 886 
for each respective protocol. Only treatment with rEtAMA1 or anti-EtAMA1 serum induced a 887 
significant reduction in parasite replication. * indicates statistical differences (P<0.05). 888 
 889 
 890 
 891 
 892 
 893 
 894 
 895 
 896 
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 897 
Fig. 3. Immunising ability of recombinant (r) Eimeria tenella apical membrane antigen (EtAMA) 1, 898 
rEtAMA2 and their combination against challenge with E. tenella H parasites (Experiment 1, n=4; 899 
Experiment 2, n=5). In each experiment a group of birds was vaccinated with the Trx-tag present in 900 
the recombinant proteins (rThioredoxin), and an additional group was mock vaccinated using PBS. 901 
Dots illustrate individual oocyst counts and bars indicate average values. Only birds vaccinated with 902 
rEtAMA1, alone or in combination, displayed a significant reduction in oocyst shedding. Groups 903 
marked with different letters were significantly different (P<0.05).  904 
 905 
 906 
 907 
 908 
 909 
 910 
 911 
 912 
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 913 
Fig. 4. Characterisation of the three different populations of Eimeria tenella expressing the Eimeria 914 
maxima apical membrane antigen 1 (EmAMA1) fused to mCherry (Ch). (A) Stabilization of transgenic 915 
populations by successive in vivo passages. Percentages indicate the total proportions of transgenic 916 
oocysts passage by passage (P1 to P3). (B) Fluorescent patterns observed by confocal microscopy in 917 
stable transgenic populations of E. tenella oocysts expressing the EmAMA1-Ch protein. mCitrine was 918 
always observed in the cytosol for all the populations, whereas mCherry was observed in the cytosol 919 
(EmAMA1-Ch, with no delivery signals), secreted into the sporocyst cavity (SP2-EmAMA1-Ch, white 920 
arrows), or secreted into the sporocyst cavity (white arrows) and anchored onto the sporozoite 921 
surface (SP2-EmAMA1-Ch-GPI, white and blue arrows respectively). In all the populations both 922 
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mCitrine and mCherry were also present within cytosolic aggregates and in some cases were co-923 
localised. Bars represent 10 µm. (C) Detection of EmAMA1-Ch transcripts in cDNA isolated from stable 924 
transgenic populations by reverse transcription (RT)-PCR. Presence of genomic DNA contamination 925 
was discarded by the use of EtActin primers that amplify a region coded between two adjacent exons 926 
(~0.1 kb, lane 1). A single band of ~1.3 kb was obtained from all three populations when specific 927 
primers targeting EmAMA1 were employed (lane 2). cDNA isolated from Eimeria maxima W strain 928 
(EmW) was included as a positive control reaction. NTC is the non-template control. 929 
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 949 
Fig. 5. Immunogenicity and efficacy of Eimeria tenella parasites expressing the Eimeria maxima apical 950 
membrane antigen 1 (EmAMA1) under the control of different delivery signals. (A) Immunising ability 951 
of Eimeria tenella Wis strain parasites expressing EmAMA1 protein fused to mCherry (Ch) and 952 
expressed under the control of different delivery signals against challenge with E. maxima W strain 953 
parasites. SP2, signal peptide from the E. tenella microneme 2 protein (EtMIC2); GPI, 954 
glycosylphosphatidylinositol -anchor from the E. tenella surface antigen 1 (EtSAG1). A group of birds 955 
was vaccinated with an empty vaccine vector (the most complete, carrying the SP2 and GPI signals), 956 
and an additional group was not vaccinated (PBS). Diamonds illustrate individual oocyst counts and 957 
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bars indicate average values. All the birds vaccinated with E. tenella parasites expressing EmAMA1-Ch 958 
displayed a significant reduction in oocyst shedding, regardless of the delivery signal included. Groups 959 
marked with different letters were significantly different (P < 0.05, one-way ANOVA test). (B) IgY 960 
responses induced after vaccination with Et[EmAMA1-Ch], Et[SP2-EmAMA1-Ch], and Et[SP2-961 
EmAMA1-Ch-GPI] by western-blot. Recombinant EmAMA1 (rEmAMA1) and E. maxima W protein 962 
extracts were separated by SDS–PAGE and probed with sera collected from vaccinated birds. Some 963 
birds strongly recognized the recombinant protein, but high variability within groups was observed. In 964 
contrast, none of the birds recognized native EmAMA1 from oocyst extracts, which could be detected 965 
with rabbit anti-rEmAMA1. (C) Quantification of IFN- and IL-10 serum levels on day 29, (8 days after 966 
the final vaccination with transgenic parasites) or at day 36 (6 days after challenge with E. maxima W, 967 
marked with ‘+ Emax’ on the axis labels). Diamonds illustrate individual serum concentrations and bars 968 
indicate average values. Letters on the right plot indicate significant differences between groups after 969 
the challenge infection (P<0.05, one-way ANOVA test). Dotted lines depict threshold values for IFN- 970 
(40 pg/ml) and IL-10 (32 pg/ml) tests. 971 
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Supplementary figure legends 984 
 985 
Supplementary Fig. S1. Sequence alignment of the Eimeria tenella apical membrane antigens 1 986 
(EtAMA1, ToxoDB Accession number ETH_00007745) and 2 (EtAMA2, ToxoDB Accession number 987 
ETH_00004860). Asterisks (*) indicate fully conserved residues. Colons (:) and periods (·) indicate 988 
conservation between groups of strongly or weakly similar properties, respectively.  989 
 990 
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 991 
Supplementary Fig. S2. Safety of transgenic vaccines based on genetically complemented Eimeria 992 
tenella parasites expressing the Eimeria maxima apical membrane antigen 1 (EmAMA1).fused to 993 
mCherry (Ch) and under the control of different delivery signals (SP2, signal peptide from the E. tenella 994 
microneme 2 protein (EtMIC2); GPI, glycosylphosphatidylinositol -anchor from the E. tenella surface 995 
antigen 1 (EtSAG1)). Individual weights from birds vaccinated with transgenic parasites expressing 996 
EmAMA1 (Et[EmAMA1-Ch], Et[SP2-EmAMA1-Ch], Et[SP2-EmAMA1-Ch-GPI]), birds vaccinated with the 997 
empty vector (Et[SP2-Ch-GPI]), and non-vaccinated birds (PBS) 7 days after the final vaccination (A) or 998 
6 days after challenge infection (‘+ Emax’, B). Triangles illustrate individual weights and bars indicate 999 
average values. No differences were found between groups (P>0.05). 1000 
 1001 
 1002 
 1003 
 1004 
 1005 
 1006 
 1007 
44 
 
 1008 
Supplementary Fig. S3. Immunising ability of Eimeria tenella Wis strain parasites expressing the 1009 
Eimeria maxima apical membrane antigen 1 (EmAMA1) under the control of the E. tenella AMA1 1010 
promoter (Et[EmAMA1]). A total of 40 3 weeks old Light Sussex chickens were split into five groups of 1011 
eight in independent wire-floored cages and housed within, coccidia-free conditions. Birds were dosed 1012 
by oral gavage with Et[EmAMA1] oocysts one (x1) or five times (x5), or with wild type E. tenella Wis 1013 
strain (Et) oocysts one (x1) or five times (x5), or with PBS. Three weeks after the last vaccination, birds 1014 
from all groups were challenged with 300 oocysts of the E. maxima W strain, and individual faecal 1015 
samples were collected from 5 to 9 days post-challenge to determine the total oocyst output. Dots 1016 
illustrate individual oocyst counts and bars indicate average values. All the birds vaccinated with 1017 
Et[EmAMA1] parasites displayed a significant reduction in oocyst shedding, regardless of the number 1018 
of doses received. Groups marked with different letters were significantly different (P<0.05). 1019 
 1020 
  1021 
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Table 1. Experimental design for the vaccine trials using recombinant (r) Eimeria tenella apical 1022 
membrane antigens 1 (EtAMA1) and 2 (EtAMA2). 1023 
Experiment n Vaccine 
Immunisation protocol Age at EtH 
challenge 
1 4 PBS 500 µl at 1, 3 and 5 wks 7 wks 
4 rThioredoxin (protein tag) 100 µg at 1, 3 and 5 wks 7 wks 
4 rEtAMA1 100 µg at 1, 3 and 5 wks 7 wks 
4 rEtAMA2 100 µg at 1, 3 and 5 wks 7 wks 
2 5 PBS 500 µl at 1, 3 and 5 wks 7 wks 
5 rThioredoxin (protein tag) 100 µg at 1, 3 and 5 wks 7 wks 
5 rEtAMA1 100 µg at 1, 3 and 5 wks 7 wks 
5 rEtAMA2 100 µg at 1, 3 and 5 wks 7 wks 
5 rEtAMA1 + rEtAMA2 100 µg at 1, 3 and 5 wks 7 wks 
 1024 
 1025 
Wks, weeks; EtH, Eimeria tenella Houghton strain. 1026 
 1027 
Table 2. Experimental design for the vaccine trials using Eimeria tenella parasites (Et) expressing the 1028 
Eimeria maxima apical membrane antigen 1 (EmAMA1).fused to mCherry (Ch) and under the control 1029 
of different delivery signals (SP2, signal peptide from the E. tenella microneme 2 protein (EtMIC2); 1030 
GPI, glycosylphosphatidylinositol -anchor from the E. tenella surface antigen 1 (EtSAG1)). 1031 
Group n Vaccine 
Immunisation  
protocol 
Age at EmW 
challenge (days) 
1 7 Et[EmAMA1-Ch] 100 oocysts at day 3 
500 oocysts at day 9 
3,000 oocysts at day 15 
5,000 oocysts at day 22 
30 
2 7 Et[SP2-EmAMA1-Ch] 30 
3 7 Et[SP2-EmAMA1-Ch-GPI] 30 
4 7 Et[SP2-GPI], empty vector 30 
5 7 PBS PBS at days 
3, 9, 15 and 22 
30 
6 7 PBS No challenge 
 1032 
EmW, Eimeria maxima Weybridge strain. 1033 
 1034 
 1035 
 1036 
 1037 
 1038 
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Table 3. Eimeria apical membrane antigen (AMA1-4) gene identities (ID), transcription profiles and 1039 
evidence of selective pressure (mean Ka/Ks ratios for six Eimeria spp. which infect chickens compared 1040 
to Eimeria tenella). Eimeria tenella gene-specific transcription profiles are presented as Fragments Per 1041 
Kilobase of transcript per Million mapped reads (FPKM) normalised against average FPKM for the full 1042 
relevant dataset.  1043 
 
E. maxima 
gene ID 
E. tenella 
gene ID 
E. tenella transcription profiles (FPKM) 
Selective 
pressure? 
UO_1c UO_2c SOc Szc Szd Mz2c Mz2d Gamd 
Mean 
Ka/Ksc 
AMA1 FN813221a ETH_00007745b 0.010 0.006 6.89 25.47 33.67 0.028 0.169 0.057 0.12 
AMA2 EMWEY_00006480b ETH_00004860b 0.000 0.000 0.041 0.015 0.029 4.21 0.510 4.612 na 
AMA3 ? ETH_00017730b 0.035 0.031 2.64 4.16 16.05 0.005 0.026 0.074 na 
AMA4 EMWEY_00022320b ETH_00013620b 0.001 0.002 2.58 2.39 2.60 1.97 2.08 3.04 0.11 
 1044 
UO, unsporulated oocyst; SO, sporulated oocyst; Sz, sporozoite; Mz2, second generation merozoite; 1045 
Gam, gametocyte.  1046 
aGenBank Accesion Number. 1047 
bToxoDB Accesion Number. 1048 
cData derived from Reid et al. (2014).  1049 
dData derived from Walker et al. (2015). 1050 
 1051 
 1052 
 1053 
 1054 
 1055 
 1056 
 1057 
 1058 
 1059 
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Table 4. Summary of genetic diversity for the Eimeria maxima and Eimeria tenella AMA1 1060 
orthologous coding sequences. Data for E. tenella are reproduced from Blake et al. (2015).   1061 
 E. maxima E. tenella 
n 18 56 
Continents sampled 3 5 
S 10 (9) 13 (13) 
dN 3 10 
dS 7 3 
K 3.49 4.04 
π Jukes Cantor 0.0028 0.0032 
H 9 8 
Hd 0.922 0.771 
Tajima’s D 0.722 (ns) 1.259 (ns) 
Fu and Li’s D* 0.953 (ns) 1.513 (0.05) 
Fu and Li’s F* 1.026 (ns) 1.688 (0.05) 
 1062 
n, the number of sequences tested; S, the number of variant sites detected, with the number of 1063 
parsimony-informative variant sites shown in parentheses; dN, the number of non-synonymous 1064 
variant sites; dS, the number of synonymous variant sites; k, the average number of pairwise 1065 
differences; π, nucleotide diversity, calculated with the Jukes Cantor correction; H, the number of 1066 
sequence haplotypes detected; Hd, the haplotype diversity; ns, not significant.  1067 
Tajima’s D and Fu and Li’s D* and F* tests were used to assess the extent or neutrality of signatures 1068 
of selection with significance (P) shown in in parentheses where relevant. 1069 
